ReviewJournal of inflammation research2026
Autophagy as a Proposed Regulatory Interface in the Gut Microbiota-Cardiovascular Axis.
Review in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut-cardiovascular axis is increasingly recognized as a contributor to cardiovascular disease (CVD) risk; however, most available evidence remains associative, and the mechanistic links between gut dysbiosis, autophagy, and cardiovascular pathology require further validation. This review proposes a conceptual framework in which autophagy may serve as a regulatory interface linking gut microbiota-derived signals with vascular and cardiac dysfunction. We summarize evidence that microbial metabolites, including trimethylamine N-oxide (TMAO), short-chain fatty acids (SCFAs), bile acids, and dysbiosis-associated products such as lipopolysaccharide (LPS), may influence autophagic flux in intestinal epithelial cells, endothelial cells, macrophages, and myocardium through pathways involving TLR-MyD88-NF-κB/NLRP3 signaling, AMPK-mTOR-ULK1-Beclin-1 regulation, and FXR/TGR5-associated mechanisms. These pathways may contribute to oxidative stress, lipid dysregulation, gut barrier dysfunction, endothelial activation, foam cell formation, and cardiovascular inflammation. We also discuss selected inflammatory and metabolic biomarkers, including PCSK9, MPO, Lp-PLA2, TMAO, and CRP, while emphasizing that their relationships with autophagy are context-dependent and, in several cases, indirect. Emerging therapeutic opportunities, including microbiome remodeling, prebiotics, probiotics, postbiotic SCFAs, high-purity eicosapentaenoic acid, PCSK9 inhibition, and autophagy-targeted nanocarriers, are evaluated with attention to their current evidence level. As many of these approaches remain supported mainly by preclinical, mechanistic, or indirect clinical evidence, future translation will require longitudinal human studies, standardized autophagy-flux assessment, multi-omics integration, and well-designed clinical trials using clinically relevant cardiovascular endpoints. Overall, this review positions the gut microbiota-autophagy-cardiovascular axis as a testable conceptual model to guide future mechanistic and translational research in CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.